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Insulin resistance plays a central role in the develop-
ment of the metabolic syndrome, but how it relates to
cardiovascular disease remains controversial. Liver
insulin receptor knockout (LIRKO) mice have pure
hepatic insulin resistance. On a standard chow diet,
LIRKO mice have a proatherogenic lipoprotein profile
with reduced high-density lipoprotein (HDL) choles-
terol and very low-density lipoprotein (VLDL) parti-
cles that are markedly enriched in cholesterol. This
is due to increased secretion and decreased clear-
ance of apolipoprotein B-containing lipoproteins,
coupled with decreased triglyceride secretion sec-
ondary to increased expression of Pgc-1b (Ppargc-
1b), which promotes VLDL secretion, but decreased
expression of Srebp-1c (Srebf1), Srebp-2 (Srebf2),
and their targets, the lipogenic enzymes and the
LDL receptor. Within 12 weeks on an atherogenic
diet, LIRKO mice show marked hypercholesterol-
emia, and 100% of LIRKO mice, but 0% of controls,
develop severe atherosclerosis. Thus, insulin resis-
tance at the level of the liver is sufficient to produce
the dyslipidemia and increased risk of atherosclero-
sis associated with the metabolic syndrome.
INTRODUCTION
Atherosclerotic cardiovascular disease is a major cause of mor-
bidity and mortality in Western society, and much effort has been
directed toward understanding its pathogenesis and identifying
the risk factors associated with it. One of the most important pre-
disposing factors for atherosclerosis is the metabolic syndrome.
The metabolic syndrome is a constellation of abnormalities in-
cluding central obesity; glucose intolerance and type 2 diabetes;
hypertension; and a dyslipidemia characterized by increased se-
rum triglycerides, decreased high-density lipoprotein (HDL) cho-
lesterol, and increased small dense low-density lipoprotein (LDL)Cparticles (Haffner et al., 1998; Grundy et al., 2004; Ford, 2005).
The metabolic syndrome affects more than 27% of adults in
the United States (Ford et al., 2004; Hedley et al., 2004) and in-
creases the risk of cardiovascular disease 2- to 3-fold (Isomaa
et al., 2001). Despite the alarming prevalence of the metabolic
syndrome and the magnitude of risk it confers, however, defining
the pathogenic links between the metabolic syndrome and car-
diovascular disease has been difficult, and even the question of
whether they are united by some common underlying patho-
physiology remains a matter of intense debate (Kahn et al.,
2005; Zimmet et al., 2005).
Insulin resistance has long been considered to be central to the
pathophysiology of the metabolic syndrome (Reaven, 1988; Bid-
dinger and Kahn, 2006). In the liver, insulin resistance is mani-
fested by the blunted ability of insulin to activate its receptor
kinase and its downstream targets (Saad et al., 1992; Kerouz
et al., 1997), resulting in incomplete suppression of hepatic glu-
cose production (Lewis et al., 1996). It is not clear, however,
whether all metabolic pathways become resistant to insulin (Shi-
momura et al., 2000; Saad et al., 1993). For example, lipogenesis,
which is positively regulated by insulin, is increased in the meta-
bolic syndrome. This could be because lipogenesis remains sen-
sitive to insulin and is driven excessively by the compensatory
hyperinsulinemia that occurs in insulin-resistant states (Reaven,
1988, 2004; Biddinger et al., 2005; Biddinger and Kahn, 2006).
Alternatively, lipogenesis could also become resistant to insulin
but be driven by other factors in the metabolic syndrome, such
as excessive carbohydrate intake (Schwarz et al., 2003).
The coexistence of hyperinsulinemia and other hormonal and
metabolic changes has made it difficult to dissect the role of in-
sulin resistance in the pathogenesis of the metabolic syndrome.
This is particularly true of very low-density lipoprotein (VLDL) se-
cretion, which is increased in the metabolic syndrome and is
thought to drive the other aspects of the dyslipidemia associated
with this disorder (Sparks and Sparks, 1994; Zammit, 2002;
Ginsberg, 1996; Ginsberg and Huang, 2000). Under normal con-
ditions, insulin targets apolipoprotein B (apoB), the principal pro-
tein component of VLDL, for intracellular degradation and
thereby decreases VLDL secretion acutely (Sparks and Sparks,
1994; Ginsberg et al., 2006). However, insulin also stimulatesell Metabolism 7, 125–134, February 2008 ª2008 Elsevier Inc. 125
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2002). Therefore, the increase in VLDL secretion associated
with the metabolic syndrome could be due either to insulin resis-
tance driving VLDL secretion by failing to degrade apoB or to
hyperinsulinemia driving VLDL secretion through excessive lipo-
genesis (Sparks and Sparks, 1994; Lewis et al., 1995; Malmstrom
et al., 1997b; Reaven, 1997; Reaven and Laws, 1994). Determin-
ing the relative roles played by insulin resistance versus hyperin-
sulinemia or other factors in the development of the dyslipidemia
associated with the metabolic syndrome remains a fundamental
but unansweredquestion with important therapeutic implications.
In the present study, we used the liver insulin receptor knockout
(LIRKO) mouseasa modelof purehepatic insulin resistance.These
mice develop hyperinsulinemia, but their livers are unable to re-
spond to it. Therefore, the LIRKO model is a unique tool with which
to dissect the effects of hepatic insulin resistance on the develop-
ment of dyslipidemia and atherosclerosis (Michael et al., 2000;
Biddinger et al., 2005). We find that triglyceride and cholesterol se-
cretion are uncoupled in LIRKO mice such that the secretion of tri-
glycerides isdecreasedbut thesecretionofapoB and cholesterol is
robust. Moreover, LDL receptor expression and the clearance of
apoB-containing particles are reduced. This results in a proathero-
genic distribution of serum cholesterol, characterized by de-
creased HDL cholesterol and an increase in cholesterol-enriched
apoB-containing lipoprotein particles. When challenged with an
atherogenic diet, LIRKO mice rapidly develop severe hypercholes-
terolemia and extensive atherosclerosis. Therefore, hepatic insulin
resistance alone can produce both dyslipidemia and the increased
risk of atherosclerosis associated with the metabolic syndrome.
RESULTS
LIRKO mice were created by breeding mice carrying insulin recep-
tor alleles modified with loxP sites with mice carrying the Cre re-
combinase driven by the albumin promoter, as described previ-
ously (Michael et al., 2000). On normal chow (9% fat with
negligible amounts of cholesterol), LIRKO mice were nonobese,
with normal serum free fatty acid levels and mildly to moderately el-
evated serum glucose levels (Table 1) relative to their littermate
controls (Lox mice). LIRKO mice also developed marked hyperin-
sulinemia due to the compensatory secretion of insulin from the
b cells of the pancreas coupled with a defect in insulin clearance
due to the lack of insulin receptors in the liver (Michael et al.,
2000). We have previously shown that the LIRKO liver fails to re-
Table 1. Phenotypic and Biochemical Characterization
of LIRKO Mice
Lox LIRKO
Weight (g) 32.7 ± 0.8 30.9 ± 0.7
Liver weight (mg/g body weight) 42.4 ± 1.2 27.1 ± 2*
Serum glucose (mg/dl) 132 ± 17 170 ± 32
Serum insulin (ng/ml) 1.1 ± 0.1 12 ± 3*
Free fatty acids (mequiv/l) 0.71 ± 0.60 0.70 ± 0.13
Hepatic triglycerides (mg/g liver) 3.58 ± 1.0 4.09 ± 0.8
Hepatic cholesterol (mg/g liver) 1.09 ± 0.06 2.09 ± 0.19*
Data were obtained from 2- to 3-month-old nonfasted LIRKO mice and
littermate Lox controls fed a standard chow diet (n = 5–8, *p < 0.05).126 Cell Metabolism 7, 125–134, February 2008 ª2008 Elsevier Inc.spond to this hyperinsulinemia, as insulin is unable to stimulate
phosphorylation of its downstream targets, the insulin receptor
substrates 1 and 2 (IRS-1 and -2), or normally suppress expression
of phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-
phosphatase (Michael et al., 2000). As observed previously, liver
weights were decreased by approximately 30%, due at least in
part todecreasedglycogenstores (Michaeletal., 2000). Hepatic tri-
glyceride content was unchanged, but there was a 2-fold increase
in hepatic cholesterol, a 4-fold increase in hepatic cholesterol
esters, and a 40% increase in free hepatic cholesterol (Table 1
and data not shown).
Dyslipidemia in LIRKO Mice
Despite the fact that serum cholesterol levels were normal
(Figure 1A) and serum triglyceride levels were reduced by 50%
(Figure 1B) on a normal chow diet, hepatic insulin resistance alone
was sufficient to produce atherogenic changes in lipoprotein me-
tabolism. Thus, fastprotein liquidchromatography (FPLC)analysis
of serum from LIRKO and Lox control mice revealed that HDL cho-
lesterol, the major formof circulating cholesterol in the mouse, was
decreased by 50%, whereas VLDL cholesterol was increased
3-fold (Figure 1C). Consistent with the decreased total serum tri-
glyceride levels, FPLC analysis also showed that VLDL and LDL/
intermediate-density lipoprotein (IDL) particles in LIRKO mice
contained reduced levels of triglycerides (Figure 1D). Concomitant
with these differences, the levels of apoB100 and apoB48, the ma-
jor lipoproteins of VLDL, LDL, and chylomicrons, were increased in
LIRKO mice, whereas the levels of apoA-I and apoE were not
(Figure 1E). Interestingly, apoE was present in the more buoyant
lipoprotein fractions of LIRKO, but not control, serum. Therefore,
even though insulin resistance did not alter total serum cholesterol
levels, it produced a distinctly proatherogenic distribution of cho-
lesterol with a shift toward apoB-containing lipoproteins.
Lipid analysis of VLDL particles isolated from these mice by
ultracentrifugation confirmed their abnormal lipid composition
(Table 2). In control mice, VLDL particles were composed largely
of triglycerides, with an 8:1 weight ratio of triglycerides to total
cholesterol. In contrast, triglycerides accounted for only 43%
of the lipids in VLDL isolated from LIRKO serum, producing
a 1:1 ratio of triglycerides to total cholesterol. Therefore, isolated
hepatic insulin resistance is sufficient to produce VLDL particles
enriched in cholesterol.
Dysregulation of PGC-1b, SREBP-1c, and SREBP-2
Several transcription factors, including the sterol regulatory ele-
ment-binding proteins (SREBPs) and their coactivators, espe-
cially peroxisome proliferator-activated receptor g coactivator
(PGC)-1b, have been shown to regulate the synthesis and secre-
tion of VLDL (Lin et al., 2005; Kalaany and Mangelsdorf, 2006;
Wolfrum and Stoffel, 2006; Horton et al., 2002) In nonfasted
mice on a standard chow diet, Pgc-1b (Ppargc-1b) and Pgc-1a
(Ppargc-1a), a related coactivator involved in regulation of gluco-
neogenic and mitochondrial gene expression (Yoon et al., 2001),
were increased 2- to 3-fold at the mRNA and protein levels
(Figure 2A). In contrast, mRNA for SREBP-1c (Srebf1), which
regulates lipogenic gene expression, and SREBP-2 (Srebf2),
which regulates expression of cholesterogenic enzymes and
the LDL receptor, were decreased by 40%–80% in LIRKO livers.
After fasting and refeeding, which normally leads to a dramatic
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1c, which represents the active form of SREBP-1c, was reduced
>95% in LIRKO livers relative to controls (Figure 2A).
Many of the targets of SREBP-2, including the cholesterogenic
enzymes HMG-CoA reductase (Hmgcr), squalene synthase (SS),
and farnesyl diphosphate synthetase (Fdps), as well as the LDL
receptor (Ldlr), were decreased by 60%–90% in LIRKO livers.
However, the targets of SREBP-1c, the genes of fatty acid and
triglyceride metabolism, showed a mixed pattern of change in
LIRKO livers. Some enzymes, like glycerol 3-phosphate acyl-
transferase (Gpat) and diacylglycerol acyltransferase (Dgat),
which are involved in the packaging of fatty acids into triglycer-
ides, and phospholipid transfer protein (Ptlp), which also traffics
lipids, were significantly increased in LIRKO livers. In contrast,
stearoyl-CoA desaturase 1 (Scd1) and fatty acid synthase (Fas)
were decreased by 40%–90%, and acetyl-CoA carboxylase
(Acc) was unchanged (Figure 2B).
Srebp-1c is regulated in part by insulin and in part by liver X re-
ceptor (LXR) (Repa et al., 2000; Tobin et al., 2002; Chen et al.,
2004; Liang et al., 2002), but how these two factors interact in
the control of Srebp-1c remains a subject of debate (Hegarty
et al., 2005; Dif et al., 2006; Cagen et al., 2005). Lxr mRNA
(Figure 2A) and protein levels (data not shown) were essentially
unchanged in LIRKO mice. To determine whether activation of
LXR could rescue lipogenic gene expression in the absence of in-Cell Metabolism 7, 125–1Figure 1. FPLC Profiles of Plasma Lipopro-
teins from Lox and LIRKO Mice
(A and B) Serum was obtained from 6-month-old
mice on a normal chow diet after a 4.5 hr fast,
and total cholesterol (A) and triglycerides (B)
were measured (n = 5–6, *p = 0.04). Error bars rep-
resent SEM.
(C and D) Serum was subjected to fast protein liq-
uid chromatography (FPLC) analysis, and choles-
terol (C) and triglycerides (D) were measured in
each of the eluted fractions. Data are presented
as the average of 2–4 mice per genotype. Similar
results were obtained in two other experiments.
(E) Apolipoprotein levels were examined by immu-
noblotting whole serum (left) or serum subjected to
fractionation by FPLC (right). FPLC samples were
prepared by pooling equal volumes of each frac-
tion from three mice.
sulin signaling, we treated LIRKO mice
and controls with an LXR agonist,
T090137, for 2 days (Figure 2C). The LXR
agonist markedly increased expression
of SREBP-1c and its lipogenic targets in
both Lox and LIRKO livers. However, ex-
pression of these genes remained signifi-
cantly lower in LIRKO livers even after
pharmacological stimulation of LXR.
Therefore, insulin action, in addition to
LXR activation, is necessary for maximal
induction of Srebp-1c and lipogenesis.
Similar results were obtained in hepato-
cytes isolated from Lox and LIRKO mice
and studied in vitro (Figure 2D), indicatingthat these effects were mediated directly by insulin resistance at
the level of the liver.
Increased Secretion and Decreased Clearance
of apoB Lipoproteins
Given the changes in gene expression and the presence of ab-
normal, cholesterol-enriched VLDL particles in LIRKO serum,
we measured VLDL secretion in chow-fed Lox and LIRKO
mice by injecting them with Triton WR1339, which inhibits lipo-
protein lipase and therefore VLDL clearance. As shown in
Figure 3A, the rate of triglyceride secretion was decreased by
66% in LIRKO mice. Three hours after injection of Triton
WR1339, VLDL was isolated by ultracentrifugation, and consis-
tent with the decreased rate of triglyceride secretion, VLDL
from LIRKO mice contained 50% less triglyceride (Figure 3B).
However, VLDL cholesterol levels were similar in control and
LIRKO mice (Figure 3C). Thus, insulin resistance in the liver leads
to an uncoupling of cholesterol and triglyceride secretion such
that only triglyceride secretion is impaired, resulting in choles-
terol-rich VLDL particles.
Given the marked effectsof hepatic insulin resistanceon lipopro-
tein metabolism, wesubjectedLIRKOmiceand theircontrols to the
stress of a Western diet, comprised of 40% fat (21% milk fat),
34.1% sucrose, 0.15% cholesterol. After 10 weeks on the Western
diet, LIRKO mice developed marked hypercholesterolemia relative34, February 2008 ª2008 Elsevier Inc. 127
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86 mg/dl in LIRKO mice; n = 5–11), demonstrating their inability
to maintain cholesterol homeostasis in the presence of excess
dietary fat and cholesterol.
Insulin normally inhibits secretion of apoB, the principal struc-
tural component of VLDL, and promotes its clearance (Sparks
and Sparks, 1994). The hypercholesterolemia of LIRKO mice on
the Western diet was due to defects in both of these processes.
Secretion of both isoforms of apoB, apoB100 and apoB48, was
increased 50%–70% in LIRKO mice (Figure 3D). On the other
hand, apoB-containing lipoprotein clearance, measured as the
fractional removal rate of radio-iodinated LDL, was markedly
reduced (Figure 3E), with an increase in LDL half-life from 1 hr
in Lox mice to more than 4 hr in LIRKO mice. Consistent with
these changes, LDLR protein (Figure 3E, inset) was decreased
90% or more in the livers of LIRKO mice on the Western diet.
Table 2. Relative Lipid Composition
Lox LIRKO
VLDL
TG 80 43
FC 5 3
CE 5 46
PL 11 8
LDL
TG 21 10
FC 15 19
CE 27 44
PL 37 27
IDL
TG 50 14
FC 13 6
CE 15 25
PL 23 55
HDL
TG 2 3
FC 14 16
CE 40 39
PL 45 42
Serum from 6-month-old mice (n = 5 of each genotype) fasted for 4.5 hr
was pooled. Lipoproteins were isolated by sequential ultracentrifugation,
and the lipid composition was determined. Data are presented as the per-
centage of total lipid (TG, triglycerides; FC, free cholesterol; CE, choles-
teryl esters; PL, phospholipids) by weight in each fraction (VLDL, very
low-density lipoprotein; LDL, low-density lipoprotein; IDL, intermediate-
density lipoprotein; HDL, high-density lipoprotein).LIRKO Mice Develop Severe Hypercholesterolemia and
Atherosclerosis on an Atherogenic Diet
The low HDL cholesterol and increase in cholesterol-rich VLDL
suggested that LIRKO mice might be more susceptible to the de-
velopment of atherosclerosis. To test this directly, we subjected
Lox and LIRKO mice to an atherogenic Paigen diet (15% dairy
fat, 1% cholesterol, 0.5% cholic acid) (Paigen et al., 1987).
This diet is high in fat and cholesterol, like the Western diet,
but it also contains cholic acid, which increases intestinal cho-128 Cell Metabolism 7, 125–134, February 2008 ª2008 Elsevier Inc.lesterol absorption and produces an even greater degree of
hypercholesterolemia. Interestingly, on this diet, although LDLR
protein was markedly decreased, Ldlr mRNA levels were similar
(see Figure S1 available online). After 2 months on the atherogenic
Paigen diet, serum cholesterol levels rose to 310 ± 24 mg/dl
in control mice but to 781 ± 98 mg/dl in LIRKO mice
(Figure 4A). FPLC fractionation revealed that the excess choles-
terol was found exclusively in the apoB-containing atherogenic
lipoproteins: VLDL, LDL, and IDL (Figure 4B). Remarkably, despite
this dramatic increase in total serum cholesterol, HDL cholesterol
levels were still significantly lower in LIRKO mice than in Lox mice.
Similar changes were observed upon FPLC analysis of serum from
mice placed on the Western diet (data not shown). In contrast, the
amount and distribution of serum triglycerides were not different
between Lox and LIRKO mice on either the atherogenic Paigen
diet (Figures 4C and 4D) or the Western diet (data not shown).
The effects of hepatic insulin resistance and the atherogenic
diet on atherosclerosis were striking. After 12 weeks on this
diet, all of the LIRKO mice of both sexes, but not a single Lox
mouse, developed overt atherosclerosis (n = 10–15 mice of
each sex per genotype). Atherosclerotic plaques were easily
visible on transillumination of the unstained aortic arch of LIRKO
mice in situ (Figure 4F, left). Oil red O staining of sections through
the aortic sinus revealed intimal fat accumulation in LIRKO mice
(Figure 4F, center). Staining of the entire aorta with Sudan IV
demonstrated disease throughout the aorta of LIRKO mice, but
no visible atheroma in control mice subjected to the same dietary
stress (Figure 4F, right). By quantitation, 1.7% of the surface of
LIRKO aortas was stained by Sudan IV, whereas no staining
was detectable in Lox aortas (Figure 4E). Thus, by multiple
criteria, LIRKO mice developed severe atherosclerosis whereas
controls did not.
DISCUSSION
Although the association between the metabolic syndrome, dys-
lipidemia, and increased cardiovascular disease risk is generally
accepted, how each of these relates to insulin resistance is con-
troversial (Kahn et al., 2005). Our studies in LIRKO mice show
that hepatic insulin resistance causes a proatherogenic distribu-
tion of serum cholesterol, with a 50% decrease in HDL choles-
terol and an increase in non-HDL cholesterol. Furthermore, on
both the Western diet and the atherogenic Paigen diet, HDL cho-
lesterol levels remained low, yet LIRKO mice developed severe
hypercholesterolemia, with the excess cholesterol associated
with apoB-containing lipoproteins, i.e., VLDL, LDL, and IDL. As
a consequence of these proatherogenic changes in lipid and
lipoprotein metabolism, LIRKO mice, but not control mice,
developed atherosclerosis within 12 weeks on an atherogenic
diet. Therefore, hepatic insulin resistance alone is sufficient for
the development of dyslipidemia and, when coupled with a per-
missive diet, the development of atherosclerosis.
Insulin resistance acts at several levels to produce dyslipide-
mia in the LIRKO mouse. First, it increases apoB secretion by
decreasing intracellular degradation of apoB (Sparks and
Sparks, 1994; Fisher et al., 2001). Second, it alters the expres-
sion of Srebp-1c, Srebp-2, Pgc-1a, and Pgc-1b. SREBP-1c,
which mediates the lipogenic response to insulin (Shimomura
et al., 1999b), is decreased in LIRKO mice, even in the presence
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SREBP-1c through mechanisms independent of LXR ligand
generation. This decrease in SREBP-1c expression results
in reduced VLDL triglyceride secretion and hypotriglyceridemia
on a chow diet. Insulin resistance also promotes the accumula-
tion of cholesterol, which inhibits SREBP-2 by preventing its
maturation (Brown and Goldstein, 1997), and thereby decreases
expression of its target, LDLR, and apoB clearance. Insulin may
also play a role in stabilizing LDLR protein since the differences
in LDLR expression were greater at the protein level than at
the mRNA level. In addition, PGC-1 expression is upregulated
in LIRKO mice, and this, along with other factors such as
Foxa2, could further increase apoB secretion (Lin et al., 2005;
Kalaany and Mangelsdorf, 2006; Wolfrum and Stoffel, 2006;
Horton et al., 2002). Finally, hepatic insulin resistance could
alter lipoprotein metabolism through secondary changes in the
hormonal and metabolic milieu, such as hyperglycemia and
hyperinsulinemia.
Dietary cholesterol and fat intake clearly interact with hepatic
insulin resistance in the production of the dyslipidemia of meta-Cell Metabolism 7, 125–1Figure 2. Insulin Resistance Alters Gene
Expression
(A) Left: expression of the transcriptional regula-
tors Pgc-1a, Pgc-1b, Lxr, Srebp-1c, and Srebp-2
was measured in the livers of 2-month-old non-
fasted mice on a chow diet by real-time PCR (n =
4–8, *p < 0.05). Right: PGC-1 protein was mea-
sured in liver extracts from 2-month-old mice sac-
rificed in the nonfasted state, and SREBP-1c was
measured in liver nuclear extracts prepared from
2-month-old mice after fasting and refeeding.
(B) Real-time PCR analysis of cDNA prepared from
livers of 2- to 4-month-old nonfasted chow-fed
mice. See text for gene names.
(C) Two-month-old Lox and LIRKO mice were gav-
aged with 40 mg/kg LXR agonist (T090137) or ve-
hicle every 24 hr for 2 days and sacrificed 4 hr after
the second dose in the nonfasted state. Real-time
PCR was performed on cDNA prepared from
these animals’ livers (n = 5–8, *p < 0.05, **p <
0.005).
(D) Hepatocytes were isolated from 2- to 3-month-
old Lox and LIRKO mice and cultured overnight in
the presence of 100 nM insulin and either 5 mM
LXR agonist or vehicle. RNA was extracted and
subjected to real-time PCR analysis (n = 4–6,
*p < 0.05).
Error bars represent SEM.
bolic syndrome. On a chow diet, serum
triglyceride levels are low and total serum
cholesterol is normal. Nonetheless, the
distribution of this cholesterol is distinctly
proatherogenic, with reduced levels of
HDL and increased levels of non-HDL
cholesterol. When LIRKO mice are chal-
lenged with a high-fat, high-cholesterol
diet, serum triglycerides normalize to
the level of Lox controls, but cholesterol
levels increase progressively to almost800 mg/dl while still retaining their atherogenic profile with low
HDL cholesterol. Therefore, hepatic insulin resistance is able to
produce a significant derangement of cholesterol metabolism
that progresses in the presence of dietary stress to marked hy-
percholesterolemia and atherosclerosis.
The distribution of serum cholesterol in LIRKO mice recapitu-
lates the dyslipidemia of the human metabolic syndrome, with in-
creased VLDL cholesterol and decreased HDL cholesterol. In
contrast, most commonly used mouse models of the metabolic
syndrome, such as leptin deficient ob/ob mice and mice with
diet-induced obesity, show increased HDL cholesterol (Table
S1). Yet LIRKO mice do not develop the hypertriglyceridemia
that is characteristic of human metabolic disease. Serum triglyc-
eride levels are under complex regulation (reviewed in Ginsberg,
1996), but one important factor driving hypertriglyceridemia is in-
sulin-stimulated hepatic de novo lipogenesis, and this is medi-
ated largely by SREBP-1c (Shimomura et al., 1998, 1999b).
Figure S2 and Table S2 show that SREBP-1c and its targets
are reduced in mice deficient in hepatic insulin signaling, such
as LIRKO mice and mice made insulinopenic by streptozotocin.34, February 2008 ª2008 Elsevier Inc. 129
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diet-induced obesity, consistent with previous reports in the lit-
erature on these and other models of the metabolic syndrome
(Biddinger et al., 2005; Shimomura et al., 1999a, 2000).
These data have led to the concept of partial insulin resis-
tance, in which defects in one arm of the insulin signaling path-
way lead to impaired control of glucose homeostasis while lipo-
genesis continues to be activated by hyperinsulinemia or some
alternative pathway (Siri et al., 2001; Biddinger et al., 2005;
Elam et al., 2001). In particular, it appears that the phosphatidyli-
nositol 3-kinase (PI3K)/Akt arm of the insulin signaling pathway,
which is thought to mediate many of insulin’s metabolic effects
(Garg, 1996), becomes resistant to insulin whereas the MAPK
arm of the insulin signaling pathway remains intact (Cusi et al.,
2000; Maezono et al., 1998). Our data are consistent with this hy-
pothesis, as restoring Akt activity in LIRKO mice on the athero-
genic diet using a constitutively active form of Akt normalizes
serum glucose and the distribution of serum cholesterol by in-
creasing HDL and decreasing non-HDL cholesterol (Figure S3).
These data further suggest that in the metabolic syndrome, insulin
resistance drives changes in cholesterol and glucose homeosta-
sis whereas hyperinsulinemia or other factors drive hypertriglycer-
idemia, and together these produce the full complement of lipid
abnormalities associated with the metabolicsyndrome inhumans.
Hypertriglyceridemia in humans is thought to decrease HDL
cholesterol through cholesteryl ester transfer protein (CETP),
an enzyme present in humans but not mice (Nagashima et al.,
1988; de Grooth et al., 2004), which removes cholesteryl esters
on HDL by exchanging them for triglycerides on VLDL (Garg,
1996; Ginsberg, 1996; Rashid et al., 2002). The fact that LIRKO
mice show a major reduction in HDL cholesterol levels even in
the absence of hypertriglyceridemia and CETP indicates that in-
sulin resistance alone can decrease HDL cholesterol indepen-
dently of hypertriglyceridemia. Although the exact mechanism
by which insulin resistance produces this effect remains to be130 Cell Metabolism 7, 125–134, February 2008 ª2008 Elsevier Inc.determined, preliminary studies show that HDL clearance is nor-
mal in LIRKO mice (S.B.B., E.F.S., D.E.C., and C.R.K., unpub-
lished data). Therefore, hepatic insulin resistance reduces HDL
cholesterol by either decreasing HDL production or promoting
a shift of HDL cholesterol to non-HDL lipoproteins.
In relating the LIRKO model to the metabolic syndrome, it is
important to remember that insulin resistance in human meta-
bolic disease differs in several respects from the LIRKO model.
First, the insulin resistance associated with the metabolic syn-
drome and type 2 diabetes involves many tissues of the body
in addition to the liver, including muscle, fat, b cells, the vascula-
ture, and other cells. Recent studies have shown that these other
tissues may also participate in the dyslipidemia and accelerated
atherosclerosis associated with these disorders. For example,
Baumgartl et al. (2006) have shown that insulin resistance in cells
of the myeloid lineage may protect against atherosclerosis in
apoE-deficient mice, whereas Han et al. (2006) found that insulin
receptor deficiency in macrophages may increase ER stress-
induced apoptosis and necrosis in advanced atherosclerotic le-
sions. Therefore, the development of dyslipidemia and athero-
sclerosis in the metabolic syndrome is ultimately dependent
upon the net effects of insulin resistance in both hepatic and ex-
trahepatic tissues. Moreover, as noted above, in human disease,
the effects of dietary and other genetic factors are superimposed
on the effects of insulin resistance in the production of the met-
abolic syndrome. Despite these differences, however, many of
the changes in cholesterol metabolism observed in the LIRKO
model are also observed in mice and humans with the metabolic
syndrome. First, obese, insulin-resistant mice and humans show
increased secretion of apoB and VLDL (Lewis et al., 1993, 1995;
Malmstrom et al., 1997a; Bartels et al., 2002; Cohen et al., 2002;
Siri et al., 2001). Second, several rodent models of obesity have
also been shown to have decreased expression of LDLR (Rob-
erts et al., 2004; Lundasen et al., 2003; Liao et al., 1997). Finally,
humans with metabolic disease show a defect in the catabolismFigure 3. VLDL Metabolism
(A–C) Two- to three-month-old chow-fed Lox and
LIRKO mice were injected with Triton WR1339 af-
ter a 6 hr fast, and serum triglycerides were mea-
sured at 0, 90, and 180 min (n = 5–7, p% 0.01 at
each time point) (A). After 180 min, serum was col-
lected, and equal volumes were pooled and sub-
jected to ultracentrifugation to obtain the very
low-density lipoprotein (VLDL) fraction. VLDL tri-
glycerides (B) and cholesterol (C) were measured.
(D and E) apoB secretion and VLDL clearance
were measured in 4-month-old mice after 10
weeks on a Western diet.
(D) The rate of apoB secretion was measured as the
amount of radiolabeled apoB100 and apoB48 pres-
ent in theserum1 hrafter injectionof Triton WR1339
and [35S]methionine, normalized to the amount
present in the Lox control (n = 4–5, *p < 0.01).
(E) Fractional clearance of low-density lipoprotein
(LDL) apoB was determined by measuring plasma
radioactivity over 24 hr after injection of 125I-labeled
mouse LDL. Results are expressed as the percent-
age of LDL radioactivity remaining in the plasma at
each time point (n = 3). Inset shows LDL receptor
(LDLR) immunoblot of liver extracts prepared from
these mice.
Error bars represent SEM.
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Liver Insulin Resistance Promotes Atherosclerosisof apoB-containing lipoproteins (Ouguerram et al., 2003; Duvil-
lard et al., 2000; Howard et al., 1987; Chan et al., 2003). There-
fore, insulin resistance in the context of the metabolic syndrome
may drive dyslipidemia and atherosclerosis by the same mech-
anisms as it does in the LIRKO model.
In summary, we have shown that insulin resistance plays a
critical and central role in the development of dyslipidemia and
atherosclerosis. This finding is of clinical importance because it
suggests that the metabolic syndrome is not merely a collection
of abnormalities that should be considered and treated indepen-
dently, as some experts have advocated (Kahn et al., 2005).
Rather, it appears that the metabolic syndrome is truly aCsyndrome, in which disturbances in glucose and cholesterol me-
tabolism both stem from a defect in insulin signaling. These data
further suggest that finding and reversing the molecular lesions
that produce the insulin resistance associated with the metabolic
syndrome will result in more effective treatment of this disorder.EXPERIMENTAL PROCEDURES
Mice, Diets, and Treatments
Generation and genotyping of LIRKO (Cre+/,IRflox/flox) mice and their littermate
Lox controls (Cre/,IRflox/flox) were performed as described previously (Mi-
chael et al., 2000). LIRKO mice were generated on a mixed geneticFigure 4. Dyslipidemia and Atherosclerosis on the Atherogenic Diet
(A–D) Serum was obtained from 4-month-old mice fed an atherogenic diet for 2 months, after a 6 hr fast. Total cholesterol (A) and triglycerides (C) were measured
in the serum. Equal amounts of serum were pooled from two mice of each genotype and subjected to FPLC fractionation. Cholesterol (B) and triglycerides (D)
were measured in each fraction. Data are presented as an average of three samples per genotype.
(E and F) Lox and LIRKO mice were placed on an atherogenic diet at 2 months of age and sacrificed 3–4 months later, at which time aortas were examined for the
presence of atherosclerosis.
(E) Quantitation of plaque areas in Lox and LIRKO mice (*p = 0.01 by Mann-Whitney U test).
(F) Left: gross dissected anatomy in situ. Middle: sections through aortic sinus and the aortic valve stained with oil red O and hematoxylin. Right: entire aorta with
adventitial fat carefully removed, flat mounted en face and stained for fat with Sudan IV.
Error bars represent SEM.ell Metabolism 7, 125–134, February 2008 ª2008 Elsevier Inc. 131
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Liver Insulin Resistance Promotes Atherosclerosisbackground, including 129Sv, C57BL/6, FVB, and DBA, and were inbred for
more than ten generations.
In most studies, mice were male, chow-fed (Purina Lab Diet 9F Mouse Chow
5020, Pharmaserv, containing 9.0% fat and 0.221 ppm cholesterol), and sac-
rificed in the nonfasted state. Alternatively, mice were given ad libitum access
to either an atherogenic Paigen diet (The Jackson Laboratory) or a Western
diet (21% milk fat, 34.1% sucrose, 0.15% cholesterol). For refeeding studies,
mice were fasted for 24 hr and then refed for 8 hr with a high-carbohydrate diet.
LXR agonist (Sigma) was prepared in 1% carboxymethylcellulose and given at
a dose of 40 mg/kg by gavage every 24 hr for 2 days to 3-month-old mice,
which were sacrificed 4 hr after the second dose in the nonfasted state. Ade-
noviruses encoding myr-Akt or LacZ (Ono et al., 2003) were prepared as pre-
viously described (Taniguchi et al., 2006) and injected into the tail vein 4 days
prior to sacrifice.
Phenotypic and Biochemical Characterization
Plasma measurements were performed using the following assays: insulin,
ELISA (Crystal Chem Inc.); leptin, ELISA (Crystal Chem Inc.); free fatty acids,
colorimetric assay (Wako); total cholesterol or triglycerides (measured as total
triglycerides), colorimetric assay (Stanbio or Sigma). Hepatic lipid analysis was
performed by the Lipid, Lipoprotein and Atherosclerosis Core of the Vanderbilt
Mouse Metabolic Phenotyping Centers as described previously (Biddinger
et al., 2006).
Fast Protein Liquid Chromatography Analysis
Serum from mice fasted 4–6 hr was subjected to FPLC as previously described
(Babaev et al., 2000). Cholesterol and triglycerides were measured in the
eluted fractions using Sigma kits 352 and 339 adapted for microtiter plates.
For apolipoprotein analysis, equal aliquots of three FPLC fractions were
pooled together and subjected to SDS-PAGE and immunoblotting with anti-
bodies against apoB, apoE, or apoA-I (Biodesign). Alternatively, equal volumes
of whole serum were subjected to immunoblotting with these antibodies.
Plasma Lipoprotein Isolation
Serum from mice fasted for 4–6 hours was collected, and equal volumes from
each genotype were pooled. The lipoproteins were isolated by sequential ul-
tracentrifugation at densities of 1.006 (VLDL), 1.019 (IDL), 1.063 (LDL), and
1.215 (HDL) as described previously (Argmann et al., 2006). Each fraction
was dialyzed against phosphate-buffered saline supplemented with EDTA
and sodium azide. Total cholesterol (Sigma), free cholesterol (Wako), total tri-
glycerides (Sigma), and phospholipids (Wako) were measured enzymatically
according to manufacturer directions.
Atherosclerosis
During deep anesthesia, animals were perfused with saline followed by forma-
lin. The base of the heart with the aortic sinus was fixed, imbedded, cryosec-
tioned, stained with oil red O, and counterstained with hematoxylin. The re-
mainder of the aorta was dissected free of adventitial fat, stained with
Sudan IV, and examined microscopically for the presence or absence of ath-
eromatous plaques. Quantitation was performed with ImageJ software (http://
rsb.info.nih.gov/ij/).
VLDL Triglyceride Secretion
Mice were fasted for 6 hr and then injected intravenously with either Triton
WR1339 (Sigma-Aldrich) or vehicle. Plasma samples were taken prior to and
90 min after injection by retro-orbital bleeds and 180 min after injection by car-
diac puncture, and total triglycerides were measured (Stanbio). Equal volumes
of serum taken at the 180 min time point were pooled and subjected to ultra-
centrifugation to isolate VLDL particles as above.
VLDL apoB Secretion
After a 4 hr fast, apoB secretion rates were determined as described previously
(Siri et al., 2001). Mice were injected with 200 mCi [35S]methionine (PerkinElmer
Life Sciences) and 500 mg/kg Triton WR1339 in normal saline. Plasma sam-
ples were collected after 60 min and subjected to SDS-PAGE and autoradiog-
raphy. The apoB100 and apoB48 bands were excised and counted in scintil-
lation fluid (Ecoscint H LS-275). The rate of apoB secretion was calculated as
the amount of radiolabeled apoB present in the serum after 1 hr.132 Cell Metabolism 7, 125–134, February 2008 ª2008 Elsevier Inc.LDL Turnover Studies
LDL (d:1.025–1.060) was isolated from the plasma of C57BL/6J male mice by
sequential ultracentrifugation, labeled with [125I]iodide monochloride (Bil-
heimer et al., 1972), dialyzed, and filter sterilized. 0.15 mCi of [125I]LDL was
injected via the femoral vein (n = 3 for each group), and radioactivity was mea-
sured in plasma samples collected at multiple time points thereafter. Mice had
free access to food and water throughout the experiment. The radioactivity
present in plasma at 30 s accounted for more than 98% of the injected LDL
and was used to calculate the percent of injected LDL remaining in the circu-
lation at the later time points.
Real-Time PCR Analysis
RNA (RNeasy, QIAGEN) was isolated from mouse liver and used as a template
for cDNA synthesis (High Capacity cDNA Synthesis Kit, Applied Biosystems)
(Biddinger et al., 2005). Quantitative real-time PCR was performed using a fluo-
rescent temperature cycler (ABI) with either SYBR Green Master Mix (Roche;
primer sequences listed in Table S4) or TaqMan Universal Master Mix (ABI;
primers purchased through Assay on Demand). Expression values were nor-
malized to the level of input RNA.
Immunoblotting of Nuclear and Liver Extracts
Nuclear extracts were prepared using 80–100 mg of liver, per the manufac-
turer’s directions (NE-PER kit, Pierce). Liver extracts were prepared by
homogenization in RIPA buffer with 1% SDS. Protein concentrations were
measured by Bradford assay (Bio-Rad). Immunoblotting was performed with
antibodies against PGC-1 (Calbiochem), SREBP-1, or LDLR (gifts from J.
Horton).
Hepatocyte Isolation
Hepatocytes were isolated from 2- to 3-month-old mice using a two-step col-
lagenase perfusion procedure, as described previously (Pertoft and Smeds-
rod, 1987). Hepatocytes were plated in collagen-coated wells in DMEM con-
taining 10% fetal bovine serum. After 3 hr, the medium was changed and
supplemented with 100 nM insulin and either 5 mM T090137 or vehicle
(DMSO). After 18 hr, cells were harvested and RNA was prepared for real-
time PCR analysis as above.
Statistical Analyses
Statistical significance was calculated by unpaired Student’s t test, and p <
0.05 was considered significant. All data are expressed as the mean ± SEM.
Supplemental Data
Supplemental Data include Supplemental Results and Discussion, Supple-
mental References, four figures, and four tables and can be found with this ar-
ticle online at http://www.cellmetabolism.org/cgi/content/full/7/2/125/DC1/.
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